Research programme: cancer therapeutics - Molecular Templates

Drug Profile

Research programme: cancer therapeutics - Molecular Templates

Alternative Names: 3F7; 5G2; MT 2289; MT 4019; MT 5050; MT 5111; MT 6868; MT-2274; MT-SAM3

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Templates
  • Developer Eli Lilly; Enzon Pharmaceuticals; Molecular Templates
  • Class Antibodies; Bacterial toxins; Drug conjugates; Recombinant proteins; Small interfering RNA
  • Mechanism of Action CD38 antigen inhibitors; ERBB 2 receptor antagonists; Immunostimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • Research Hodgkin's disease
  • No development reported Breast cancer; Cancer; Malignant melanoma

Most Recent Events

  • 14 Nov 2017 Molecular Templates intends to submit an IND application to the US FDA for a phase I trial of MT 4019 in Multiple myeloma in mid-2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top